Kush Dalal

发表

The SecY complex forms a channel capable of ionic discrimination

F. Duong, Kush Dalal, 2009, EMBO reports.

Two copies of the SecY channel and acidic lipids are necessary to activate the SecA translocation ATPase

S. Sligar, F. Duong, Kush Dalal, 2012, Proceedings of the National Academy of Sciences.

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

J. Dye, J. Mascola, J. M. Sauder, 2022, Cell Reports.

On the quaternary structure and gating of the bacterial protein translocation channel

Kush Dalal, 2012 .

Modulation of the SecY channel permeability by pore mutations and trivalent cations

Huan Bao, F. Duong, Kush Dalal, 2010, Channels.

Cheminformatics Driven Development of Novel Therapies for Drug Resistant Prostate Cancer

P. Rennie, F. Ban, A. Cherkasov, 2018, Molecular informatics.

Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.

P. Rennie, F. Ban, A. Cherkasov, 2014, Journal of medicinal chemistry.

Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer

Fariba Ghaidi, M. Gleave, L. McIntosh, 2017, Oncotarget.

Nanodiscs unravel the interaction between the SecYEG channel and its cytosolic partner SecA

S. Sligar, F. Duong, Kush Dalal, 2007, The EMBO journal.

Structure, Binding, and Activity of Syd, a SecY-interacting Protein*

G. Brayer, N. Nguyen, R. Maurus, 2009, Journal of Biological Chemistry.

Selectively Targeting the DNA-binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer*

P. Rennie, F. Ban, Kriti Singh, 2014, The Journal of Biological Chemistry.

Reconstitution of the SecY translocon in nanodiscs.

F. Duong, Kush Dalal, 2010, Methods in molecular biology.

Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner

M. Gleave, Yuzhuo Wang, P. Rennie, 2016, Oncotarget.

Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.

P. Rennie, J. Peacock, F. Ban, 2018, Cancer letters.

Sequential Action of MalE and Maltose Allows Coupling ATP Hydrolysis to Translocation in the MalFGK2 Transporter*

E. Cytrynbaum, Huan Bao, F. Duong, 2015, The Journal of Biological Chemistry.

Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer

P. Rennie, A. Cherkasov, Kush Dalal, 2013, International journal of molecular sciences.

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).

M. Gleave, L. Fazli, E. Beraldi, 2018, European urology.

Androgen receptor binding sites are highly mutated in prostate cancer

A. Gursoy, M. Gönen, Tunc Morova, 2017, bioRxiv.

Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions

M. Gleave, Rendong Yang, P. Rennie, 2017, Molecular Cancer Therapeutics.

Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors

P. Rennie, F. Ban, Kriti Singh, 2015, Cells.

Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.

P. Rennie, F. Ban, A. Cherkasov, 2018, European journal of medicinal chemistry.

Design and Selection of IFI16-PAAD Mutants with Improved dsDNA Destabilization Properties

F. Pio, Kush Dalal, Desmond K. W. Lau, 2016 .

RPA nucleic acid-binding properties of IFI16-HIN200.

F. Pio, P. Youkharibache, Kush Dalal, 2008, Biochimica et biophysica acta.

Thermodynamics and stability of the PAAD/DAPIN/PYRIN domain of IFI‐16

F. Pio, Kush Dalal, 2006, FEBS letters.

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

J. Dye, J. Mascola, J. M. Sauder, 2021, bioRxiv.

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

P. Rennie, F. Ban, Kriti Singh, 2015, The Journal of Biological Chemistry.

Structure-Activity Analysis of Niclosamide Reveals Potential Role for Cytoplasmic pH in Control of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling*

N. Sonenberg, R. Andersen, T. Alain, 2012, The Journal of Biological Chemistry.

The SecY complex: conducting the orchestra of protein translocation.

F. Duong, Kush Dalal, 2011, Trends in cell biology.

Best Practices of Computer-Aided Drug Discovery: Lessons Learned from the Development of a Preclinical Candidate for Prostate Cancer with a New Mechanism of Action

Artem Cherkasov, Huifang Li, Fuqiang Ban, 2017, J. Chem. Inf. Model..

Targeting Semaphorin 3C in Prostate Cancer With Small Molecules

M. Gleave, J. Peacock, A. Cherkasov, 2018, Journal of the Endocrine Society.

Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers

P. Rennie, Kriti Singh, A. Cherkasov, 2018, International journal of molecular sciences.

Drug-Discovery Pipeline for Novel Inhibitors of the Androgen Receptor.

P. Rennie, A. Cherkasov, Kush Dalal, 2016, Methods in molecular biology.

SecYEG activates GTPases to drive the completion of cotranslational protein targeting

K. Shen, F. Duong, Kush Dalal, 2013, The Journal of cell biology.

The maltose ABC transporter: action of membrane lipids on the transporter stability, coupling and ATPase activity.

I. Rouiller, Huan Bao, F. Duong, 2013, Biochimica et biophysica acta.

Androgen receptor-binding sites are highly mutated in prostate cancer

M. Gönen, Tunc Morova, N. Lack, 2020, Nature Communications.

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

J. Dye, J. Mascola, J. M. Sauder, 2022, Cell Reports.

Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer

B. McConeghy, Michael Hsing, Kush Dalal, 2024, Scientific reports.

Cheminformatics Driven Development of Novel Therapies for Drug Resistant Prostate Cancer

P. Rennie, A. Cherkasov, Kush Dalal, 2018, Molecular informatics.